

Single-dose administration and the influence of the time
immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD
four randomised trials

Lancet, The

397, 881-891

DOI: [10.1016/s0140-6736\(21\)00432-3](https://doi.org/10.1016/s0140-6736(21)00432-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Third-Party Materials. , 2020, , 144-144.		0
2	COVID-19 vaccines. Farmacist Ro, 2021, 1, 7.	0.0	0
3	Vaccination for COVID-19 control and considerations for Australia. Microbiology Australia, 2021, 42, 30.	0.1	2
4	Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?. Journal of Korean Medical Science, 2021, 36, e124.	1.1	64
5	Managing Two-Dose COVID-19 Vaccine Rollouts with Limited Supply. SSRN Electronic Journal, 0, , .	0.4	10
6	COVID-19 vaccines & pandemic. Indian Journal of Medical Research, 2021, 153, 517.	0.4	5
7	Cable News and COVID-19 Vaccine Compliance. SSRN Electronic Journal, 0, , .	0.4	9
8	Reactogenicity and Immunogenicity of Heterologous ChAdOx1-nCoV19 and BNT162b2 Vaccination: A Systematic Review and Meta-Analysis of the Heterologous COVID-19 Vaccination Outcomes. SSRN Electronic Journal, 0, , .	0.4	1
10	COVID-19 vaccines: implementation, limitations and opportunities. Global Health & Medicine, 2021, 3, 1-5.	0.6	28
15	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	1.7	19
20	Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19. Drug Design, Development and Therapy, 2021, Volume 15, 1345-1356.	2.0	1
21	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrology Dialysis Transplantation, 2021, 36, 1160-1168.	0.4	38
23	Human vaccines & immunotherapeutics: news. Human Vaccines and Immunotherapeutics, 2021, 17, 932-933.	1.4	0
24	Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. PLoS Pathogens, 2021, 17, e1009406.	2.1	16
25	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses, 2021, 13, 418.	1.5	51
29	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics, 2021, 11, 579.	1.3	114
30	The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 163-165.	0.2	6
31	Single-dose Oxfordâ€AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet, The, 2021, 397, 854-855.	6.3	55

#	ARTICLE	IF	CITATIONS
33	COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3554.	1.2	47
35	SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1376-1386.	0.6	28
36	Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2405-2406.	1.1	4
38	A Two-Phase Stochastic Dynamic Model for COVID-19 Mid-Term Policy Recommendations in Greece: A Pathway towards Mass Vaccination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2497.	1.2	17
39	Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study. <i>PLoS ONE</i> , 2021, 16, e0250797.	1.1	9
41	Short-term impact of nursing home SARS-CoV-2 vaccinations on new infections, hospitalizations, and deaths. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2063-2069.	1.3	52
42	Pandemic moves and countermoves: vaccines and viral variants. <i>Lancet, The</i> , 2021, 397, 1326-1327.	6.3	29
43	Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. <i>European Respiratory Journal</i> , 2021, 58, 2100956.	3.1	115
45	Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada. <i>BMC Public Health</i> , 2021, 21, 706.	1.2	13
46	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , 2021, 9, 341.	2.1	24
47	The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World. <i>Clinical Therapeutics</i> , 2021, 43, 702-710.	1.1	7
48	Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. <i>Vaccine</i> , 2022, 40, 2506-2513.	1.7	108
51	Lessons from the United Kingdom's COVID-19 vaccination strategy. <i>Medical Journal of Australia</i> , 2021, 214, 417-419.	0.8	6
52	Evaluation of COVID-19 vaccination strategies with a delayed second dose. <i>PLoS Biology</i> , 2021, 19, e3001211.	2.6	111
53	An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. <i>Oral Diseases</i> , 2022, 28, 2583-2585.	1.5	15
54	Reporting of AstraZeneca studies may have caused vaccine reservations. <i>BMJ, The</i> , 2021, 373, n937.	3.0	0
55	Informing COVID-19 vaccination priorities based on the prevalence of risk factors among adults in Canada. <i>Cmaj</i> , 2021, 193, E617-E621.	0.9	9
56	Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. <i>Nature Medicine</i> , 2021, 27, 993-998.	15.2	161

#	ARTICLE	IF	CITATIONS
58	SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6, .	2.3	72
59	Are Vaccines Effective and Safe for the Prevention of COVID-19 Infections? A Living Systematic Review. Acta Medica Philippina, 2021, 55, .	0.0	1
60	An assessment of the impact of the vaccination program on coronavirus disease 2019 (COVID-19) outbreaks in care homes in Northern Irelandâ€”A pilot study. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.0	4
62	Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us â€” and what they don't. European Respiratory Journal, 2021, 58, 2101111.	3.1	20
63	In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease. Viruses, 2021, 13, 792.	1.5	30
64	Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine, 2021, 39, 2360-2365.	1.7	30
65	Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nature Reviews Immunology, 2021, 21, 330-335.	10.6	98
66	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
67	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
68	Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian Perspective. Vaccines, 2021, 9, 423.	2.1	3
70	Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science, 2021, 372, 363-370.	6.0	185
71	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Frontiers in Immunology, 2021, 12, 656362.	2.2	29
72	Thromboembolism and the Oxfordâ€”AstraZeneca COVID-19 vaccine: side-effect or coincidence?. Lancet, The, 2021, 397, 1441-1443.	6.3	136
74	Comparisons of Motivation to Receive COVID-19 Vaccination and Related Factors between Frontline Physicians and Nurses and the Public in Taiwan: Applying the Extended Protection Motivation Theory. Vaccines, 2021, 9, 528.	2.1	19
76	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood, 2021, 138, 299-303.	0.6	125
78	COVID-19 Rapid Guideline - Organisation and Management in Low Resource Countries. The Physician, 2021, 7, 1-14.	0.2	0
79	Correspondence on â€”Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortâ€™. Annals of the Rheumatic Diseases, 2021, 80, e159-e159.	0.5	18
80	Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. Vaccine, 2021, 39, 2995-3006.	1.7	71

#	ARTICLE	IF	CITATIONS
81	Promising Immunotherapies against COVID-19. <i>Advanced Therapeutics</i> , 2021, 4, 2100044.	1.6	4
83	Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	55
84	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ, The</i> , 2021, 373, n1088.	3.0	881
85	The UK approach to COVID-19 vaccination: why was it so different?. <i>Drugs in Context</i> , 2021, 10, 1-9.	1.0	3
86	COVID-19: vaccine™s progress. <i>Microbial Biotechnology</i> , 2021, 14, 1246-1257.	2.0	16
87	Development of leading first-generation vaccines against SARS-CoV-2. <i>Microbes and Infection</i> , 2021, 23, 104841.	1.0	0
92	A Blueprint to Control the SARS-CoV-2 Pandemic. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1128-1131.	1.4	0
93	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
94	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
95	<scp>COVID</scp>-19: vaccination problems. <i>Environmental Microbiology</i> , 2021, 23, 2878-2890.	1.8	46
96	Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. <i>BMJ, The</i> , 2021, 373, n1114.	3.0	298
97	An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1813-1818.	1.9	84
98	Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.2	15
99	Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?. <i>Infectious Diseases Now</i> , 2021, 51, 402-405.	0.7	4
100	Landscape and selection of vaccine epitopes in SARS-CoV-2. <i>Genome Medicine</i> , 2021, 13, 101.	3.6	30
101	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates – Authors' reply. <i>Lancet, The</i> , 2021, 397, 2248.	6.3	9
104	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
105	Future developments in the prevention, diagnosis and treatment of COVID-19. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 73, 56-80.	1.4	4

#	ARTICLE	IF	CITATIONS
106	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
108	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
109	Quantitative SARS-CoV-2 anti-spike responses to Pfizerâ€™BioNTech and Oxfordâ€™AstraZeneca vaccines by previous infection status. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1516.e7-1516.e14.	2.8	100
110	Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 741-753.	1.8	9
111	COVIDâ€™19 in gastroenterology: Where are we now? Current evidence on the impact of COVIDâ€™19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021, 9, 750-765.	1.6	18
112	The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3297-3309.	1.4	6
113	Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1539-1548.	4.6	115
114	ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 240-254.	2.4	12
115	Updates on the coronavirus disease 2019 vaccine and consideration in children. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 328-338.	0.9	8
116	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates. <i>Lancet</i> , The, 2021, 397, 2247-2248.	6.3	3
117	Comparison of neutralizing antibody responses against <scp>SARSâ€™CoV</scp>â€™2 in healthy volunteers who received the <scp>BNT162b2 mRNA</scp> or the <scp>AZD1222</scp> vaccine: Should the second <scp>AZD1222</scp> vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021, 96, E321-E324.	2.0	17
118	How long does covid-19 immunity last?. <i>BMJ</i> , The, 2021, 373, n1605.	3.0	36
119	Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 793-802.	4.6	453
121	Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms. <i>Kidney International</i> , 2021, 99, 1492-1494.	2.6	50
122	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
123	Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. <i>Transplantation Direct</i> , 2021, 7, e713.	0.8	11
124	How important is the second dose of the COVID-19 mRNA vaccine?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2537.	2.0	3
125	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <i>Scientific Reports</i> , 2021, 11, 11998.	1.6	17

#	ARTICLE	IF	CITATIONS
127	Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19. <i>Neurology and Therapy</i> , 2021, , 1-17.	1.4	6
128	What should define a SARS-CoV-2 breakthrough infection?. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	18
129	COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. <i>Expert Review of Vaccines</i> , 2021, 20, 857-880.	2.0	32
131	Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. <i>Vaccines</i> , 2021, 9, 582.	2.1	65
132	Interpreting vaccine efficacy trial results for infection and transmission. <i>Vaccine</i> , 2021, 39, 4082-4088.	1.7	55
133	Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1529-1538.	4.6	146
134	Chronic Immune Activation and CD4+ T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 693269.	2.2	6
136	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	1.1	55
138	Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination. <i>Nature Communications</i> , 2021, 12, 3449.	5.8	101
139	Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. <i>Blood Cancer Journal</i> , 2021, 11, 136.	2.8	100
141	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1784-1789.	2.8	54
142	Personalized health and the coronavirus vaccinesâ€”Do individual genetics matter?. <i>BioEssays</i> , 2021, 43, e2100087.	1.2	9
143	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. <i>BMC Medicine</i> , 2021, 19, 173.	2.3	156
144	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1654-1664.	4.6	200
145	Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 939-949.	4.6	744
146	Mandatory immunization against SARS-CoV-2 of athletes, companions and supporters for the Tokyo Olympics. <i>International Journal of Infectious Diseases</i> , 2021, 108, 156-158.	1.5	2
149	Response to: The new context in which breakthrough infections might emerge. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.2	0
150	Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. <i>Lancet</i> , The, 2021, 398, 385-387.	6.3	366

#	ARTICLE	IF	CITATIONS
151	Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
152	Efficiency in COVID-19 Vaccination Campaigns – A Comparison across Germany’s Federal States. <i>Vaccines</i> , 2021, 9, 788.	2.1	10
153	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
154	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	15.2	337
155	Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study. <i>Medical Journal Armed Forces India</i> , 2021, 77, S283-S288.	0.3	41
156	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. <i>Infection</i> , 2022, 50, 11-25.	2.3	50
159	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , 2021, 3, 212-228.	0.3	7
162	Evaluating the Impact of Vaccination on COVID-19 Using Model Checking. , 2021, , .		0
163	Navigating post-vaccine COVID-19 futures in the health and economic context. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 893-894.	4.6	3
164	Symptom study app provides real-world data on COVID-19 vaccines. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 890-891.	4.6	3
166	Effectiveness of COVID-19 vaccines: findings from real world studies. <i>Medical Journal of Australia</i> , 2021, 215, 149.	0.8	56
167	Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
168	Efficacy of COVID-19 vaccines: From clinical trials to real life. <i>Therapie</i> , 2021, 76, 277-283.	0.6	30
169	Effectiveness of ChAdOx1 nCoV-19 Vaccine: Experience of a tertiary care institute. <i>Medical Journal Armed Forces India</i> , 2021, 77, S271-S277.	0.3	13
170	An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	40
171	Response to letter: Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.2	1
173	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
174	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. <i>Current Biology</i> , 2021, 31, R918-R929.	1.8	246

#	ARTICLE	IF	CITATIONS
175	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 121-130.	6.3	316
177	Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102184.	1.8	27
182	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. <i>Scientific Reports</i> , 2021, 11, 15531.	1.6	70
183	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. <i>Clinical Infectious Diseases</i> , 2022, 74, 1208-1219.	2.9	64
185	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. <i>Pain and Therapy</i> , 2021, 10, 1309-1330.	1.5	28
186	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	0.9	17
187	The conundrum of two-dose interval of ChAdOx1 nCoV-19 corona virus vaccine: Way ahead. <i>Medical Journal Armed Forces India</i> , 2021, 77, S250-S253.	0.3	3
188	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
189	COVID-19 vaccines: what do we know so far?. <i>FEBS Journal</i> , 2021, 288, 4996-5009.	2.2	7
190	COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4108-4111.	1.4	30
191	Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model. <i>Royal Society Open Science</i> , 2021, 8, 210530.	1.1	33
192	Oxford's AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign. <i>Public Health</i> , 2021, 196, 135-137.	1.4	10
193	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
194	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. <i>Npj Vaccines</i> , 2021, 6, 97.	2.9	175
195	DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice. <i>Vaccines</i> , 2021, 9, 874.	2.1	16
196	Information in Spanish on YouTube about Covid-19 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3916-3921.	1.4	8
197	Numbers of spontaneous reports: how to use and interpret?. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	10
199	Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	27

#	ARTICLE	IF	CITATIONS
201	SARS-CoV-2 Vaccines: Where Are We Now?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3535-3543.	2.0	36
202	Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. <i>Nature Nanotechnology</i> , 2021, 16, 843-850.	15.6	40
203	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329.	0.5	188
204	The COVID-19 Vaccination Strategy in Brazil—A Case Study. <i>Epidemiologia</i> , 2021, 2, 338-359.	1.1	6
206	A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy. <i>Vaccines</i> , 2021, 9, 915.	2.1	10
209	SARS-CoV-2 vaccines—the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
210	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
211	Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination—a risk-benefit analysis for people aged 60 years in Australia. <i>Vaccine</i> , 2021, 39, 4784-4787.	1.7	25
212	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
213	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. <i>Frontiers in Microbiology</i> , 2021, 12, 637554.	1.5	8
214	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
215	The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 903-910.	0.6	22
217	Making US poison centers a part of the solution to the COVID-19 pandemic. <i>Clinical Toxicology</i> , 2021, , 1-13.	0.8	1
218	Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics. <i>Indian Journal of Medical Microbiology</i> , 2021, 39, 417-422.	0.3	5
220	Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1533.	3.8	331
221	Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12580.	1.0	11
222	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3459-3476.	1.1	179
225	A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. <i>EClinicalMedicine</i> , 2021, 38, 101001.	3.2	45

#	ARTICLE	IF	CITATIONS
226	Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021, 61, 2837-2843.	0.8	29
227	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
229	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021, 12, e0100221.	1.8	7
230	COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series. <i>Medicina (Lithuania)</i> , 2021, 57, 891.	0.8	12
231	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
232	SARS-CoV-2 Vaccination in Children and Adolescents—A Joint Statement of the European Academy of Paediatrics and the European Confederation for Primary Care Paediatricians. <i>Frontiers in Pediatrics</i> , 2021, 9, 721257.	0.9	17
234	Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0110521.	1.8	21
235	A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection. <i>Pathogens</i> , 2021, 10, 1078.	1.2	0
236	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	2.8	103
237	Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. <i>Postgraduate Medical Journal</i> , 2022, 98, 389-394.	0.9	137
238	Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. <i>BMJ, The</i> , 2021, 374, n2015.	3.0	223
239	Corneal graft rejection following COVID-19 vaccine. <i>Eye</i> , 2022, 36, 1319-1320.	1.1	40
240	To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. <i>Expert Review of Vaccines</i> , 2021, 20, 1211-1220.	2.0	85
241	Effect of Vaccination on Transmission of SARS-CoV-2. <i>New England Journal of Medicine</i> , 2021, 385, 1718-1720.	13.9	150
242	Prophylactic vaccine delivery systems against epidemic infectious diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113867.	6.6	22
243	Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. <i>Medical Journal of Australia</i> , 2021, 215, 427-432.	0.8	20
244	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
245	Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. <i>Vaccine</i> , 2021, 39, 6492-6509.	1.7	95

#	ARTICLE	IF	CITATIONS
246	Randomized Double-Blind, Placebo-Controlled Feasibility Study, Evaluating the Efficacy of Homeopathic Medicines in the Prevention of COVID-19 in a Quarantined Population. <i>Homeopathy</i> , 2022, 111, 049-056.	0.5	13
247	Adverse events and preventive measures related to COVID-19 vaccines. <i>Clinical and Experimental Emergency Medicine</i> , 2021, 8, 153-159.	0.5	1
248	COVID-19: Critical appraisal of the evidence. <i>Anales De PediatrĀa (English Edition)</i> , 2021, 95, 207.e1-207.e13.	0.1	7
249	Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine. <i>Lancet, The</i> , 2021, 398, 933-935.	6.3	3
250	Responsive and agile vaccination strategies against COVID-19 in India. <i>The Lancet Global Health</i> , 2021, 9, e1197-e1200.	2.9	13
251	Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. <i>Clinical Infectious Diseases</i> , 2022, 75, e792-e804.	2.9	73
253	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV,the</i> , 2021, 8, e568-e580.	2.1	124
254	Autoimmunity roots of the thrombotic events after COVID-19 vaccination. <i>Autoimmunity Reviews</i> , 2021, 20, 102941.	2.5	39
255	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	5.8	40
256	Failures of quarantine systems for preventing COVID-19 outbreaks in Australia and New Zealand. <i>Medical Journal of Australia</i> , 2021, 215, 320-324.	0.8	47
257	Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries. <i>AJOG Global Reports</i> , 2021, 1, 100020.	0.4	6
258	The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. <i>Vaccines</i> , 2021, 9, 1101.	2.1	11
259	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	13.9	458
260	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
261	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	48
262	An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2. <i>Future Science OA</i> , 2021, 7, FSO739.	0.9	2
263	Optimising SARS-CoV-2 vaccination schedules. <i>Lancet, The</i> , 2021, 398, 819-821.	6.3	3
264	Shooting at a Moving TargetĀEffectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22

#	ARTICLE	IF	CITATIONS
266	The impact of prioritisation and dosing intervals on the effects of COVID-19 vaccination in Europe: an agent-based cohort model. <i>Scientific Reports</i> , 2021, 11, 18812.	1.6	13
267	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
268	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
269	How will mass-vaccination change COVID-19 lockdown requirements in Australia?. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100224.	1.3	32
270	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
271	Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210214.	1.5	13
272	COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases. <i>Ear, Nose and Throat Journal</i> , 2024, 103, NP104-NP107.	0.4	26
275	Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. <i>Viruses</i> , 2021, 13, 1782.	1.5	70
276	Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. <i>Journal of the Neurological Sciences</i> , 2021, 428, 117607.	0.3	168
279	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
280	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
281	Safety and Immunogenicity of a Recombinant Adenovirus Type-5â€“Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged â‰¥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e783-e791.	2.9	71
283	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
284	Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 738049.	1.2	7
286	Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. <i>Vaccines</i> , 2021, 9, 989.	2.1	90
288	Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 113-121.	0.6	113
290	Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 880.e1-880.e4.	0.6	27
291	Pausing drugs and spacing vaccines: an open question â€“ Authors' reply. <i>Lancet Rheumatology, The</i> , 2021, 3, e683-e684.	2.2	0

#	ARTICLE	IF	CITATIONS
293	Animal models of SARS-CoV-2 transmission. <i>Current Opinion in Virology</i> , 2021, 50, 8-16.	2.6	21
294	Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. <i>EClinicalMedicine</i> , 2021, 40, 101126.	3.2	60
295	Administration of COVID-19 vaccines in immunocompromised patients. <i>International Immunopharmacology</i> , 2021, 99, 108021.	1.7	51
297	From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. <i>Environmental Research</i> , 2021, 201, 111555.	3.7	8
298	Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 102, 105937.	1.7	50
299	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
300	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. , 2022, , 342-349.		4
301	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
302	COVID-19 vaccine effectiveness in preventing deaths among high-risk sgroups in Tamil Nadu, India. <i>Indian Journal of Medical Research</i> , 2021, 153, 689.	0.4	7
303	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
304	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. <i>Pediatric Infection and Vaccine</i> , 2021, 28, 7.	0.1	7
305	Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers. <i>Epidemiology and Infection</i> , 2021, 149, e157.	1.0	23
306	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
307	Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. <i>Journal of Korean Medical Science</i> , 2021, 36, e107.	1.1	57
310	Generation of efficacy data on 60 years and older population using SARS-CoV-2 vaccines. <i>MGM Journal of Medical Sciences</i> , 2021, 8, 289.	0.1	0
311	Reactogenicity After Heterologous and Homologous COVID-19 Prime-Boost Vaccination Regimens: Descriptive Interim Results of a Comparative Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
312	Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India. <i>Epidemiology and Infection</i> , 2021, 149, e224.	1.0	18
313	ImmunitÄts- und Impfbescheinigungen in der Coronakrise. , 2021, , 151-162.		0

#	ARTICLE	IF	CITATIONS
315	Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members. <i>JAMA Internal Medicine</i> , 2021, 181, 1589.	2.6	15
316	COVID vaccination: What's next?. <i>Practice Nursing</i> , 2021, 32, 420-421.	0.1	0
317	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
318	SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2021, 45, 1.	0.6	9
319	Trastornos de coagulación después de la vacunación ChAdx1 nCoV-19 contra la COVID-19. <i>Revista Peruana De Investigación En Salud</i> , 2021, 5, 329-331.	0.0	0
320	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
321	Actions and attitudes on the immunized patients against SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, , .	0.5	3
322	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
323	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
325	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
328	Synergistic Effects of Natural Compounds Toward Inhibition of SARS-CoV-2 3CL Protease. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5708-5718.	2.5	8
329	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
330	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. <i>International Journal of Infectious Diseases</i> , 2022, 114, 165-174.	1.5	18
331	Correspondence. <i>Deutsches Ärzteblatt International</i> , 2021, 118, 722.	0.6	0
332	Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1086.	1.1	9
333	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
334	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. <i>Lancet</i> , The, 2021, 398, 1683-1684.	6.3	47
335	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. <i>Immunity and Ageing</i> , 2021, 18, 38.	1.8	20

#	ARTICLE	IF	CITATIONS
336	Vaccines against COVID-19: Priority to mRNA-Based Formulations. <i>Cells</i> , 2021, 10, 2716.	1.8	17
338	Exploration of the Experience of Care Home Managers of COVID-19 Vaccination Programme Implementation and Uptake by Residents and Staff in Care Homes in Northern Ireland. <i>Vaccines</i> , 2021, 9, 1160.	2.1	3
339	Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. <i>Vaccines</i> , 2021, 9, 1147.	2.1	8
340	Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. <i>Nature</i> , 2021, 600, 701-706.	13.7	180
341	SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method—A Small Real-World Sample Exploration. <i>Vaccines</i> , 2021, 9, 1139.	2.1	7
342	National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan. <i>Surgery Today</i> , 2022, 52, 763-773.	0.7	7
343	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127.	1.5	6
345	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	24
346	Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health Care Workers: A Prospective Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0178821.	1.8	9
347	No one is safe until we are all safe. <i>Science Translational Medicine</i> , 2021, 13, eabl9900.	5.8	5
350	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. <i>Cell Reports Medicine</i> , 2021, 2, 100448.	3.3	11
351	Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study. <i>Thrombosis Research</i> , 2021, 208, 1-3.	0.8	7
352	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
353	Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. <i>Nature Communications</i> , 2021, 12, 6220.	5.8	62
354	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
355	Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study. <i>Lancet, The</i> , 2021, 398, 1825-1835.	6.3	119
356	Erythema nodosum following the first dose of ChAdOx1 nCoV-19 vaccine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	17
357	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102

#	ARTICLE	IF	CITATIONS
358	Eventos adversos pós-vacinação contra o SARS-CoV-2 (covid-19) no estado de Minas Gerais. Revista De Saude Publica, 2021, 55, 66.	0.7	9
359	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 1930.	3.8	140
361	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
362	Decisive conditions for strategic vaccination against SARS-CoV-2. Chaos, 2021, 31, 101105.	1.0	4
364	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. Nature Communications, 2021, 12, 6370.	5.8	3
365	Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Regions, 2021, 1, 124-129.	0.5	12
366	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.4	4
367	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Epidemiology and Infection, 2021, 149, 1-24.	1.0	43
368	Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine, 2021, 39, 7429-7440.	1.7	19
370	A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Nature Communications, 2021, 12, 6277.	5.8	18
371	Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. EBioMedicine, 2021, 73, 103679.	2.7	67
372	Is Mandatory Vaccination for COVID-19 Constitutional under Brazilian Law?. Health and Human Rights, 2021, 23, 163-174.	1.3	3
373	Thrombotic events and COVID-19 vaccines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 701-707.	0.6	4
375	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. Journal of Infectious Diseases, 2022, 225, 327-331.	1.9	12
376	Viral-vectored vaccines against SARS-CoV-2. , 2022, , 115-127.		1
377	Thrombotic events and COVID-19 vaccines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 701-707.	0.6	19
378	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e42-e52.	2.2	66
380	COVID-19 vaccinations: The unknowns, challenges, and hopes. Journal of Medical Virology, 2022, 94, 1336-1349.	2.5	75

#	ARTICLE	IF	CITATIONS
381	Vaccines and Vaccination Strategies for Older Adults. <i>Healthy Ageing and Longevity</i> , 2022, , 119-164.	0.2	1
382	Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database. <i>Vaccines</i> , 2021, 9, 1326.	2.1	38
383	SARS-CoV-2 transmission across age groups in France and implications for control. <i>Nature Communications</i> , 2021, 12, 6895.	5.8	11
384	Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2021, 11, 22777.	1.6	159
385	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. <i>Journal of Thoracic Oncology</i> , 2022, 17, 239-251.	0.5	51
387	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
388	COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. <i>Journal of Medical Virology</i> , 2022, 94, 1294-1299.	2.5	69
389	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	1.9	21
390	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
391	Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost. <i>Frontiers in Immunology</i> , 2021, 12, 776933.	2.2	24
392	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
393	A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19 "Recovered Patients. <i>Viral Immunology</i> , 2021, , .	0.6	6
394	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
398	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
400	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
402	A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. <i>EClinicalMedicine</i> , 2021, 42, 101218.	3.2	21
404	Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report. <i>Acta Neurochirurgica</i> , 2022, 164, 543-547.	0.9	16
405	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57

#	ARTICLE	IF	CITATIONS
406	A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. <i>Clinical Infectious Diseases</i> , 2022, 75, e888-e891.	2.9	25
407	12-month SARS-CoV-2 antibody persistency in a Tyrolean COVID-19 cohort. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1265-1271.	1.0	2
408	The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered-Dose Inhaler in the Treatment of COVID-19 Patients. <i>Recent Advances in Drug Delivery and Formulation</i> , 2021, 15, .	0.3	0
410	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. <i>PLoS ONE</i> , 2021, 16, e0258645.	1.1	13
411	Previous COVID-19 Infection and Antibody Levels After Vaccination. <i>Frontiers in Public Health</i> , 2021, 9, 778243.	1.3	69
412	The influence of interval between doses on response to vaccines. <i>Vaccine</i> , 2021, 39, 7123-7127.	1.7	9
413	Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2. <i>Communications Biology</i> , 2021, 4, 1365.	2.0	21
414	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110582.	1.5	9
415	An Analysis of Conspiracy Beliefs of Covid-19 Vaccination in Ghana. <i>Advances in Journalism and Communication</i> , 2021, 09, 196-208.	0.1	2
416	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
417	Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines. <i>Einstein (Sao Paulo, Brazil)</i> , 2021, 19, eED6840.	0.3	0
418	Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVACDM cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 849-858.	2.2	45
420	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. <i>Journal of Infection</i> , 2022, 84, 675-683.	1.7	87
422	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100154.	1.5	55
423	A model predictive control approach to optimally devise a two-dose vaccination rollout: A case study on COVID-19 in Italy. <i>International Journal of Robust and Nonlinear Control</i> , 2023, 33, 4808-4823.	2.1	25
424	Vaccination against COVID-19: Factors That Influence Vaccine Hesitancy among an Ethnically Diverse Community in the UK. <i>Vaccines</i> , 2022, 10, 106.	2.1	28
425	Extended interval BNT162b2 vaccination enhances peak antibody generation. <i>Npj Vaccines</i> , 2022, 7, 14.	2.9	101
426	Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 1-9.	0.3	5

#	ARTICLE	IF	CITATIONS
427	Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 161-168.	3.6	147
429	Neutralization Assessments Reveal High Cardiothoracic Ratio and Old Age as Independent Predictors of Low Neutralizing Antibody Titers in Hemodialysis Patients Receiving a Single Dose of COVID-19 Vaccine. <i>Journal of Personalized Medicine</i> , 2022, 12, 68.	1.1	7
430	Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2. <i>Royal Society Open Science</i> , 2022, 9, 211021.	1.1	8
431	Analyses of Confirmed COVID-19 Cases Among Korean Military Personnel After Mass Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, e23.	1.1	4
432	Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers. <i>Journal of Medical Virology</i> , 2022, 94, 2008-2018.	2.5	11
433	Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women. <i>Expert Review of Vaccines</i> , 2022, , 1-3.	2.0	0
434	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
435	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
436	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. <i>BMC Medicine</i> , 2022, 20, 29.	2.3	20
437	Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis. <i>Vaccine</i> , 2022, 40, 587-593.	1.7	6
438	Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. <i>Cureus</i> , 2022, 14, e21721.	0.2	4
439	Initial comparative analysis of pulmonary involvement on HRCT between vaccinated and non-vaccinated subjects of COVID-19. <i>European Radiology</i> , 2022, 32, 4275-4283.	2.3	17
440	A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. <i>Molecular Diversity</i> , 2022, 26, 2631-2645.	2.1	3
441	Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1073.	1.2	4
442	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. <i>Lancet</i> , 2022, 399, 25-35.	6.3	109
443	New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA. <i>Avicenna Journal of Medical Biotechnology</i> , 2022, 14, 30-36.	0.2	6
444	Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective. <i>International Journal of Public Health</i> , 2021, 66, 1604312.	1.0	4
445	Knowledge barriers in a national symptomatic-COVID-19 testing programme. <i>PLOS Global Public Health</i> , 2022, 2, e0000028.	0.5	11

#	ARTICLE	IF	CITATIONS
446	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. <i>EBioMedicine</i> , 2022, 75, 103761.	2.7	104
447	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 649-656.	4.6	12
448	Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 279.	3.8	68
449	Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2022, 226, 485-496.	1.9	8
450	Control strategies of an SIVS network model with two vaccinations. <i>Journal of the Franklin Institute</i> , 2022, , .	1.9	4
451	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	1.5	18
452	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. <i>American Journal of Epidemiology</i> , 2022, 191, 800-811.	1.6	53
453	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
454	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COVS.S Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	13.9	102
455	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). <i>Scientific Reports</i> , 2022, 12, 1727.	1.6	11
456	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
457	COVID-19 vaccine reactogenicity â€œ A cohort event monitoring study in the Netherlands using patient reported outcomes. <i>Vaccine</i> , 2022, 40, 970-976.	1.7	17
458	COVID-19 Vaccination for Frail Older Adults in Singapore - Rapid Evidence Summary and Delphi Consensus Statements. <i>Journal of Frailty & Aging,the</i> , 2022, 11, 236-241.	0.8	3
459	Effectiveness of Covishield vaccine in preventing Covid-19 â€œ A test-negative case-control study. <i>Vaccine</i> , 2022, 40, 3294-3297.	1.7	19
460	Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. <i>Nature Immunology</i> , 2022, 23, 380-385.	7.0	78
461	COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study. <i>Vaccines</i> , 2022, 10, 253.	2.1	6
462	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. <i>Lancet, The</i> , 2022, 399, 814-823.	6.3	196
463	Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England. <i>Journal of Infection</i> , 2022, 84, 692-700.	1.7	13

#	ARTICLE	IF	CITATIONS
464	Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 291-303.	1.0	23
465	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
468	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
469	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6574-6585.	2.5	9
470	Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 591-598.	2.0	7
471	Post-COVID-19 Vaccine Parosmia: A Case Report. <i>Cureus</i> , 2021, 13, e20292.	0.2	3
472	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021, 12, 7217.	5.8	80
473	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
474	Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. <i>Expert Review of Vaccines</i> , 2022, 21, 261-267.	2.0	40
475	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1701-1709.	1.9	9
477	A case report of ChAdOx1 nCoV-19 vaccine-associated encephalitis. <i>BMC Neurology</i> , 2021, 21, 485.	0.8	24
478	Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
479	Vaccines against SARS-CoV-2. , 2022, , 201-222.		0
480	Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
481	Covishield, (ChAdOx1) vaccine effectiveness and epidemiological risk factors of COVID-19 infection among frontline workers during second wave of COVID-19 pandemic, New Delhi: A case-control study. <i>Journal of Marine Medical Society</i> , 2022, 24, 101.	0.0	0
482	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105
484	Nuevos retos en el desarrollo y uso de vacunas contra la COVID-19.. , 2022, 25, 8-14.		0
485	Fighting Fire with Fire: Immunogenicity of Viral Vected Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	1.5	4

#	ARTICLE	IF	CITATIONS
486	Population antibody responses following COVID-19 vaccination in 212,102 individuals. <i>Nature Communications</i> , 2022, 13, 907.	5.8	94
487	Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine—A Study Protocol. <i>Frontiers in Medicine</i> , 2022, 9, 761655.	1.2	4
488	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350.	2.1	44
489	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10
490	Exploring Data and Literature Currently Available on the COVID-19 Vaccines. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 7-12.	0.4	1
491	The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection. <i>Vaccines</i> , 2022, 10, 338.	2.1	5
492	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
493	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. <i>Frontiers in Neurology</i> , 2022, 13, 828616.	1.1	4
494	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
495	Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. <i>Vaccines</i> , 2022, 10, 324.	2.1	9
496	Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. <i>Vaccines</i> , 2022, 10, 323.	2.1	1
497	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. <i>Frontiers in Microbiology</i> , 2022, 13, 828806.	1.5	17
498	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5
499	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. <i>Vaccines</i> , 2022, 10, 312.	2.1	3
500	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2. <i>Vaccines</i> , 2022, 10, 322.	2.1	8
503	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. <i>Nature Computational Science</i> , 2022, 2, 123-131.	3.8	39
504	SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status. <i>Vacunas</i> , 2022, 23, S70-S71.	1.1	2
505	The unnaturalistic fallacy: COVID-19 vaccine mandates should not discriminate against natural immunity. <i>Journal of Medical Ethics</i> , 2022, 48, 371-377.	1.0	22

#	ARTICLE	IF	CITATIONS
506	Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2. <i>Nature Communications</i> , 2022, 13, 1639.	5.8	8
507	SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1511-1514.	0.6	3
508	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
509	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
510	Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	9
512	SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?. <i>Vaccines</i> , 2022, 10, 444.	2.1	11
513	Was Alpha deadlier than wild-type COVID? Analysis in rural England. <i>Infection</i> , 2022, 50, 1171-1178.	2.3	3
515	Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands. <i>Drug Safety</i> , 2022, 45, 319-331.	1.4	31
516	Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
518	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 801870.	2.0	13
519	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
520	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	6
521	Perceived risk and perceptions of COVID-19 vaccine: A survey among general public in Pakistan. <i>PLoS ONE</i> , 2022, 17, e0266028.	1.1	14
522	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0
523	Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases. <i>BMJ Case Reports</i> , 2022, 15, e244638.	0.2	9
524	Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13152.	1.3	5
525	A Statistical Analysis of Covid-19 Pandemic Based on the Temporal Evolution of Entropy in Different Countries. <i>Turkish Journal of Public Health</i> , 0, , .	0.5	0
526	Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	12

#	ARTICLE	IF	CITATIONS
527	Effectiveness of COVID-19 vaccines. <i>Journal of Infection</i> , 2022, 84, e118-e119.	1.7	5
528	Humoral response to viral vector COVID-19 vaccine in hemodialysis patients. <i>Kidney Research and Clinical Practice</i> , 2022, , .	0.9	7
529	ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago. <i>Vaccines</i> , 2022, 10, 466.	2.1	6
530	Vaccines Against COVID-19: A Review. <i>Vaccines</i> , 2022, 10, 414.	2.1	8
531	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0228321.	1.8	5
532	Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization. <i>BMC Medicine</i> , 2022, 20, 119.	2.3	14
533	Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2. <i>PLoS Computational Biology</i> , 2022, 18, e1009978.	1.5	10
535	Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study. <i>Medical Journal Armed Forces India</i> , 2022, , .	0.3	1
536	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1
537	Current status of COVID-19 vaccination: safety and liability concern for children, pregnant and lactating women. <i>Expert Review of Vaccines</i> , 2022, 21, 825-842.	2.0	3
538	The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis. <i>European Journal of Public Health</i> , 2022, 32, 648-654.	0.1	1
539	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 766-777.	0.8	22
540	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
541	Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. <i>EClinicalMedicine</i> , 2022, 46, 101344.	3.2	7
543	Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. <i>Vaccine: X</i> , 2022, 10, 100153.	0.9	25
544	Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 933-950.	1.6	14
545	Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. <i>Med</i> , 2022, 3, 249-261.e4.	2.2	56
546	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	1.5	24

#	ARTICLE	IF	CITATIONS
547	Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105156.	1.6	5
548	Effect of two vaccine doses in the SEIR epidemic model using a stochastic cellular automaton. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2022, 597, 127258.	1.2	13
549	Penyuluhan Vaksinasi Covid-19 di Desa Malitu. , 2021, 1, 51-55.		0
550	Effectiveness and Safety of COVID-19 Vaccine. <i>Trends in the Sciences</i> , 2021, 26, 10_18-10_25.	0.0	0
551	Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 435.	7.1	11
552	ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. <i>Endoscopy</i> , 2022, 54, 211-216.	1.0	12
553	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 156.	2.9	15
554	A Narrative Review of COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 62.	2.1	40
555	An episode of transmission of COVID-19 from a vaccinated healthcare worker to co-workers. <i>Infectious Diseases</i> , 2022, 54, 297-302.	1.4	3
556	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
557	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 123.	3.1	10
558	The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19. <i>Musculoskeletal Care</i> , 2022, 20, 431-441.	0.6	6
560	Criteria for judging the immune markers of COVID-19 disease vaccines. <i>MedComm</i> , 2022, 3, 1-12.	3.1	3
561	ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin-6. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12630.	1.0	7
562	An Overview of COVID-19 and Its Vaccines. <i>Biology Bulletin Reviews</i> , 2021, 11, 47-64.	0.3	0
563	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	1.6	44
564	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
566	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. <i>Vaccines</i> , 2022, 10, 37.	2.1	15

#	ARTICLE	IF	CITATIONS
567	Modelling the Human Immune System Response to the ChAdOx1 nCoV-19 Vaccine. , 2021, , .		0
568	Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Medicine, 2022, 19, e1003926.	3.9	51
569	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
570	Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar. BMC Public Health, 2022, 22, 724.	1.2	9
571	Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	14
572	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases, 2022, 9, .	0.4	62
573	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. Lancet Regional Health - Europe, The, 2022, 17, 100381.	3.0	15
574	Humoral antibody response to the first dose of the <sc>ChAdOx1 nCoV</sc> â€19 vaccine in Asian patients undergoing hemodialysis. Hemodialysis International, 2022, , .	0.4	2
576	Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis. Vaccines, 2022, 10, 596.	2.1	14
577	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. Clinical Infectious Diseases, 2022, 75, 1980-1992.	2.9	92
578	Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data. Vaccine, 2022, 40, 3203-3209.	1.7	13
579	Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on COVID-19 Infection in Kidney Transplant Recipients. Vaccines, 2022, 10, 572.	2.1	3
580	Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy. Vaccines, 2022, 10, 623.	2.1	2
581	CT severity score: an imaging biomarker to estimate the severity of COVID-19 pneumonia in vaccinated and non-vaccinated population. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	4
582	A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, 47.	2.9	6
584	Clinico-Epidemiological Profile of Breakthrough COVID-19 Infection among Vaccinated Beneficiaries from a COVID-19 Vaccination Centre in Bihar, India.. Ethiopian Journal of Health Sciences, 2022, 32, 15-26.	0.2	1
585	Validation and performance of a multiplex serology assay to quantify antibody responses following SARSâ€CoVâ€2 infection or vaccination. Clinical and Translational Immunology, 2022, 11, e1385.	1.7	10
586	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0

#	ARTICLE	IF	CITATIONS
587	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
588	Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort study. <i>SeÅenovskij Vestnik</i> , 2021, 13, 14-23.	0.3	0
590	Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population. <i>Viruses</i> , 2022, 14, 946.	1.5	14
591	An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. <i>Vaccines</i> , 2022, 10, 655.	2.1	11
592	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
593	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. <i>Med</i> , 2022, 3, 406-421.e4.	2.2	17
594	Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. <i>Journal of Medical Virology</i> , 2022, 94, 4071-4087.	2.5	5
595	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
596	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
597	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
598	Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. <i>Nature Medicine</i> , 2022, 28, 1476-1485.	15.2	24
599	COVID-19 vaccination challenges: A mini-review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	5
600	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
601	Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. <i>Antibodies</i> , 2022, 11, 35.	1.2	3
602	Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine. <i>Diabetology International</i> , 2022, 13, 637-643.	0.7	6
603	Analyzing COVID-19 vaccine efficacy in vulnerable communities: efforts beyond addressing vaccine inequity. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1053-1054.	2.8	1
604	Superficial venous thrombosis as a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports. <i>Journal of Medical Case Reports</i> , 2022, 16, 182.	0.4	3
605	Clinical Differences Between Elderly and Non-elderly Patients with COVID-19. , 2022, 23, 238-245.		2

#	ARTICLE	IF	CITATIONS
606	Dynamic planning of a two-dose vaccination campaign with uncertain supplies. <i>European Journal of Operational Research</i> , 2023, 304, 1269-1278.	3.5	4
607	Probable Vogt's "Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review. <i>Vaccines</i> , 2022, 10, 783.	2.1	11
608	Acute interstitial nephritis after COVID-19 vaccination. <i>BMJ Case Reports</i> , 2022, 15, e246841.	0.2	10
609	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
612	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
614	Impacts of a delayed and slow-paced vaccination on cases and deaths during the COVID-19 pandemic: a modelling study. <i>Journal of the Royal Society Interface</i> , 2022, 19, .	1.5	2
615	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003953.	3.9	27
616	ASSESSMENT OF THE HUMORAL IMMUNITY INDUCED BY SPUTNIK V COVID-19 VACCINE (GAM-COVID-VAC) IN HEALTHCARE WORKERS. <i>Vacunas (English Edition)</i> , 2022, . .	0.3	0
617	A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme. <i>Epidemics</i> , 2022, 39, 100581.	1.5	2
618	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. <i>EBioMedicine</i> , 2022, 80, 104073.	2.7	28
619	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
620	Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study. <i>Vaccines</i> , 2022, 10, 822.	2.1	2
621	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
622	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ, The</i> , 0, , e069989.	3.0	78
623	Changing Dynamics of SARS-CoV-2: A Global Challenge. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5546.	1.3	3
624	Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	9
625	Acute macular neuroretinopathy after COVID-19 vaccine. <i>Journal Francais D'Ophthalmologie</i> , 2022, 45, e299-e302.	0.2	6
626	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26

#	ARTICLE	IF	CITATIONS
628	First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India. <i>BMJ Global Health</i> , 2022, 7, e008271.	2.0	6
629	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
630	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
631	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
632	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	21
633	Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County—Results from a Population-Based Longitudinal Study in Germany. <i>Viruses</i> , 2022, 14, 1168.	1.5	4
634	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
635	ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. <i>Vaccines</i> , 2022, 10, 959.	2.1	3
636	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. <i>Journal of Infection</i> , 2022, 85, 306-317.	1.7	12
638	Optimizing Spatio-Temporal Allocation of the COVID-19 Vaccine Under Different Epidemiological Landscapes. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
640	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 2212-2225.	6.3	23
641	Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield™) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. <i>Vaccines</i> , 2022, 10, 970.	2.1	6
642	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	0.9	8
643	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1049-1060.	5.2	24
644	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. <i>MBio</i> , 2022, 13, .	1.8	9
645	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. <i>Translational Research</i> , 2022, 249, 13-27.	2.2	5
646	Presence of SARS-CoV-2 Antibodies among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
647	COVID-19 vaccine-induced thrombotic thrombocytopenia. <i>Canadian Family Physician</i> , 2022, 68, 434-437.	0.1	1

#	ARTICLE	IF	CITATIONS
648	Delayed Booster Dosing Improves Human Antigen-Specific IG and B Cell Responses to the RH5.1/AS01 <sub>B</sub>; Malaria Vaccine. SSRN Electronic Journal, 0, , .	0.4	0
649	Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis. , 2022, , 559-582.		0
651	Comparison of COVID-19 Vaccines Introduced in Korea. Biomedical Science Letters, 2022, 28, 67-82.	0.0	1
653	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerging Microbes and Infections, 2022, 11, 1890-1899.	3.0	12
654	Current state of COVID-19 in pregnancy. Gynecology, 2022, 24, 206-211.	0.1	0
655	Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey. Cureus, 2022, , .	0.2	2
656	Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study. International Journal of Infectious Diseases, 2022, 122, 693-702.	1.5	25
657	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine, 2022, 81, 104128.	2.7	8
658	Should we allocate more COVID-19 vaccine doses to non-vaccinated individuals?. PLOS Global Public Health, 2022, 2, e0000498.	0.5	1
659	The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. Therapie, 2023, 78, 293-302.	0.6	1
660	EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 â€“ AN OVERVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 6-16.	0.3	1
661	COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review. Frontiers in Immunology, 0, 13, .	2.2	24
662	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19â€™BNT162b2 mRNA Vaccination. Viruses, 2022, 14, 1470.	1.5	5
663	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine, 2022, 50, 101529.	3.2	3
664	Insights into COVID-19 vaccines development: Translation from benchside to bedside. Health Sciences Review, 2022, 4, 100040.	0.6	1
665	Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India. Vaccines, 2022, 10, 1153.	2.1	11
666	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science, 2022, 377, 890-894.	6.0	142
667	Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. Scientific Reports, 2022, 12, .	1.6	7

#	ARTICLE	IF	CITATIONS
668	Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100685.	3.3	11
670	COVID-19 Vaccination in China: Adverse Effects and Its Impact on Health Care Working Decisions on Booster Dose. <i>Vaccines</i> , 2022, 10, 1229.	2.1	8
672	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
673	Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4127-4136.	1.1	8
674	Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience. <i>Vaccines</i> , 2022, 10, 1224.	2.1	5
675	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
676	Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 187-191.	0.8	4
677	Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. <i>Vaccine</i> , 2022, 40, 5585-5593.	1.7	3
678	Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya. <i>BMJ Global Health</i> , 2022, 7, e009430.	2.0	14
679	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
680	Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. <i>Vaccine</i> , 2022, 40, 5701-5708.	1.7	0
681	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	2.1	8
682	SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. <i>Viruses</i> , 2022, 14, 1861.	1.5	4
683	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. <i>Nature Communications</i> , 2022, 13, .	5.8	33
685	Detection of Short-Term Side Effects of ChAdOx1 nCoV-19 Vaccine: A Cross-Sectional Study in a War-Torn Country. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 13, 85-91.	1.1	4
686	New onset of acute uveitis following COVID-19 vaccination. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 0, , .	1.0	2
688	Comparison of the 2021 COVID-19 roadmap projections against public health data in England. <i>Nature Communications</i> , 2022, 13, .	5.8	21
689	Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0

#	ARTICLE	IF	CITATIONS
690	Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19â€“Vaccinated Priority Groups. American Journal of Tropical Medicine and Hygiene, 2022, 107, 850-855.	0.6	2
691	Modelling non-linear patterns of time-varying intervention effects on recurrent events in infectious disease prevention studies. Journal of Biopharmaceutical Statistics, 2023, 33, 220-233.	0.4	2
693	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	4.2	12
694	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
695	Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Experimental Hematology and Oncology, 2022, 11, .	2.0	18
696	Evolution and control of the COVID-19 pandemic: A global perspective. Cities, 2022, 130, 103907.	2.7	13
697	Antibody Response and Safety of ChAdOx1-nCoV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study. Digestive Diseases and Sciences, 2023, 68, 676-684.	1.1	6
698	A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nature Communications, 2022, 13, .	5.8	13
699	Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom. Expert Opinion on Drug Safety, 2023, 22, 343-349.	1.0	8
701	Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.. Immunology Letters, 2022, 250, 1-6.	1.1	3
702	Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review. Saudi Journal for Health Sciences, 2022, 11, 83.	0.1	1
703	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
704	Antibody profile in post-vaccinated & SARS-CoV-2â€“infected individuals. Indian Journal of Medical Research, 2022, .	0.4	1
705	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq1 1 0.784314 rgBT ₂ Overlook	0.4	0
706	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. SSRN Electronic Journal, 0, , .	0.4	0
707	SARS-CoV-2 Infection Concurrent with Acute Stroke: A Case Study of Aged People Partially Vaccinated Against COVID-19. Re:GEN Open, 2022, 2, 98-102.	0.7	0
708	Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222). BioScientific Review, 2022, 4, 1-20.	0.0	0
709	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Frontiers in Microbiology, 0, 13, .	1.5	14

#	ARTICLE	IF	CITATIONS
710	SARS-CoV-2 Infections in Vaccinated and Unvaccinated Populations in Camp Lemonnier, Djibouti, from April 2020 to January 2022. <i>Viruses</i> , 2022, 14, 1918.	1.5	0
711	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. <i>Life</i> , 2022, 12, 1318.	1.1	3
712	SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status. <i>Vacunas (English Edition)</i> , 2022, 23, S72-S73.	0.3	0
713	Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1907-1916.	1.0	3
714	Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil. <i>Vaccine</i> , 2022, 40, 6722-6729.	1.7	3
715	Intentions of Patients with Hypertension to Receive a Booster Dose of the COVID-19 Vaccine: A Cross-Sectional Survey in Taizhou, China. <i>Vaccines</i> , 2022, 10, 1635.	2.1	2
716	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
717	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
718	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. <i>PLoS Pathogens</i> , 2022, 18, e1010802.	2.1	27
719	Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12-18 years group. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1937-1940.	0.8	2
721	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44
722	Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
723	Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos. <i>Medicina Y Laboratorio</i> , 2022, 26, 383-389.	0.0	0
724	Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 45, 102595.	1.7	2
727	An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. <i>Vaccines</i> , 2022, 10, 1546.	2.1	1
729	Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
730	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
731	The Post-Vaccination Quantitative Total Immunoglobulin Levels against SARS-CoV-2 in Healthcare Workers: A Multi-Centric Cohort Study in India. <i>Vaccines</i> , 2022, 10, 1535.	2.1	0

#	ARTICLE	IF	CITATIONS
732	Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil. <i>Vaccine</i> , 2022, 40, 6616-6624.	1.7	8
733	Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
734	Cable news and COVID-19 vaccine uptake. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
735	Development of variant-agnostic severe acute respiratory syndrome coronavirus 2, pan-coronavirus, and pan-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
736	Uptake of COVID-19 booster shot among healthcare workers: A mediation analysis approach. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
737	Mechanical prosthetic valve thrombosis after ChAdOx1-nCoV-19 vaccination: A case report. <i>IHJ Cardiovascular Case Reports (CVCR)</i> , 2022, , .	0.0	0
738	Managing two-dose COVID-19 vaccine rollouts with limited supply: Operations strategies for distributing time-sensitive resources. <i>Production and Operations Management</i> , 2022, 31, 4424-4442.	2.1	17
740	The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern. <i>PLoS Pathogens</i> , 2022, 18, e1010882.	2.1	8
741	Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1518, 209-225.	1.8	4
742	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10
743	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. <i>Nature Communications</i> , 2022, 13, .	5.8	15
744	Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2205-2217.	1.8	22
746	Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
747	Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. <i>Vaccines</i> , 2022, 10, 1706.	2.1	3
748	Knocking on heaven's door: The gap between health institutions and academies in generating knowledge utilizing real-world data. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
749	Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review. <i>Biomedica</i> , 2022, 42, 19-31.	0.3	2
750	Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver Cirrhosis. <i>Vaccines</i> , 2022, 10, 1837.	2.1	6
751	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	4.6	14

#	ARTICLE	IF	CITATIONS
753	Comparative risk of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination or infection: A national cohort study using linked electronic health records. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
755	Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study. <i>Hormones</i> , 0, , .	0.9	3
756	Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 398-407.	2.9	24
758	Inoculation works and health advocacy backfires: Building resistance to COVID-19 vaccine misinformation in a low political trust context. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	4
759	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
760	COVID-19 Vaccination in Kidney Transplant Candidates and Recipients. <i>Vaccines</i> , 2022, 10, 1808.	2.1	6
761	In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
762	Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
763	Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	5
764	A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2022, 15, 1212-1224.	1.9	2
765	An Analysis of the COVID-19 Situation in India in Terms of Testing, Treatment, Vaccine Acceptance and National Economic Performance. <i>International Journal of Public Health</i> , 0, 67, .	1.0	1
766	Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, 212-223.	1.5	21
767	Ten commonly asked questions about COVID-19 vaccines from a group of the saudi population, King Abdulaziz Medical City, Riyadh. <i>Asian Journal of Pharmaceutical Research and Health Care</i> , 2022, 14, 181.	0.0	0
768	Immune correlates analysis of the ENSEMBLE single Ad26.CO2.S dose vaccine efficacy clinical trial. <i>Nature Microbiology</i> , 2022, 7, 1996-2010.	5.9	39
769	The Association of Time of Day of ChAdOx1 nCoV-19 Vaccine Administration With SARS-CoV-2 Anti-Spike IgG Antibody Levels: An Exploratory Observational Study. <i>Journal of Biological Rhythms</i> , 2023, 38, 98-108.	1.4	2
770	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. <i>Biomedicines</i> , 2022, 10, 2892.	1.4	4
771	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. <i>Expert Review of Vaccines</i> , 2022, 21, 1739-1761.	2.0	2
772	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 27-45.	1.9	6

#	ARTICLE	IF	CITATIONS
773	The attitude of fully vaccinated individuals towards COVID-19 vaccine booster dose: a transverse study from Jordan. <i>Journal of Pharmaceutical Health Services Research</i> , 0, , .	0.3	1
774	Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. <i>Drug Safety</i> , 2023, 46, 65-75.	1.4	6
775	Cerebral venous sinus thrombosis following intracerebral hemorrhage after <scp>COVID</scp>â€19 <scp>AstraZeneca</scp> vaccination: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	8
777	Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerlandâ€A multicentre cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004125.	3.9	11
778	Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
779	Reactogenicity and Immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers. <i>Yonsei Medical Journal</i> , 0, 63, .	0.9	5
780	Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
781	Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2â€Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	3
782	Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. <i>Vaccine</i> , 2022, , .	1.7	0
783	Post-vaccination adverse reactions, decision regret, and willingness to pay for the booster dose of COVID-19 vaccine among healthcare workers: A mediation analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
784	Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14341.	1.8	4
785	Comparison of HRCT chest findings among vaccinated and non-vaccinated COVID-19 patients. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 2911.	0.0	0
786	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
787	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2897-2925.	5.7	1
788	Efficacy and Safety of COVID-19 Vaccinesâ€An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
789	Six Months Follow-Up Study on Health Care Workers on Persistence of Antibodies to SARS-CoV-2 after Covishield Vaccination. <i>Journal of Evolution of Medical and Dental Sciences</i> , 0, , 884-887.	0.1	0
790	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
791	Adverse Events of COVID-19 Vaccination among the Saudi Population: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 2089.	2.1	3

#	ARTICLE	IF	CITATIONS
792	The Importance of Fostering and Funding Scientific Research, and its Relevance to Environmental Toxicology and Chemistry. <i>Environmental Toxicology and Chemistry</i> , 2023, 42, 581-593.	2.2	0
793	ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys. <i>Npj Vaccines</i> , 2022, 7, .	2.9	7
794	Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 1403-1411.	2.9	52
795	Mixing age and risk groups for accessing COVID-19 vaccines: a modelling study. <i>BMJ Open</i> , 2022, 12, e061139.	0.8	1
796	Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV. <i>Journal of Virus Eradication</i> , 2022, 8, 100308.	0.3	2
797	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
798	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
799	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
800	Differences in BNT126b2 and ChAdOx1 Homologous Vaccination Antibody Response among Teachers in Poznan, Poland. <i>Vaccines</i> , 2023, 11, 118.	2.1	0
802	Taste Detection Threshold in Relation to Pfizer COVID-19 Vaccine. <i>Cureus</i> , 2023, , .	0.2	0
803	COVID-19 Vaccines – All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
804	Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease. <i>Indian Journal of Gastroenterology</i> , 2023, 42, 64-69.	0.7	4
805	Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis. <i>International Immunopharmacology</i> , 2023, 115, 109728.	1.7	14
806	COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. <i>EclinicalMedicine</i> , 2023, 56, 101823.	3.2	12
807	The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7811-7821.	1.1	2
808	Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily. <i>Healthcare (Switzerland)</i> , 2023, 11, 305.	1.0	3
809	Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity. <i>Cureus</i> , 2023, , .	0.2	0
810	Mathematical models and simulations of different scenarios of COVID-19 in Brazil. <i>Revista De Matemática: Teoria Y Aplicaciones</i> , 2023, 30, 87-111.	0.1	0

#	ARTICLE	IF	CITATIONS
811	Evaluation of COVID-19 Vaccination Rate in Healthcare Workers in a Tertiary Hospital in Mogadishu Somalia: A Cross-sectional Study. , 2023, 2, 1-11.		0
812	Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
814	A brief overview of various vaccines against nCOVID19, including safety, efficacy, reported cases, clinical trials, and progress. <i>Indian Journal of Health Sciences and Biomedical Research KLEU</i> , 2023, 16, 13.	0.1	1
815	Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. <i>JCI Insight</i> , 2023, 8, .	2.3	13
816	Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. <i>Eurosurveillance</i> , 2023, 28, .	3.9	0
817	Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants. <i>International Journal of Infectious Diseases</i> , 2023, 129, 19-31.	1.5	6
818	COVID-19 Vaccination in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 135.	1.0	9
820	Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. <i>PLoS ONE</i> , 2023, 18, e0281673.	1.1	2
821	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
822	Efficacy of SARS-CoV-2 vaccines and the doseâ€“response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
823	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2â€“ seropositive individuals. , 2023, 2, 100083.		2
824	Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. <i>Nature Communications</i> , 2023, 14, .	5.8	36
825	Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants. <i>Pathogens</i> , 2023, 12, 211.	1.2	5
826	Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2â€“18 years: an updated systematic review and meta-analysis. <i>World Journal of Pediatrics</i> , 2023, 19, 1041-1054.	0.8	8
827	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. <i>Chinese Medical Journal</i> , 2023, 136, 24-33.	0.9	2
828	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. <i>Pathogens</i> , 2023, 12, 244.	1.2	8
829	COVID-19 therapy and vaccination: a clinical narrative review. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	10
830	T Cell Responses to SARS-CoV-2. <i>Annual Review of Immunology</i> , 2023, 41, 343-373.	9.5	48

#	ARTICLE	IF	CITATIONS
831	The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England. <i>Nature Communications</i> , 2023, 14, .	5.8	8
832	A recombinant <i>Mycobacterium smegmatis</i> -based surface display system for developing the T cell-based COVID-19 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
833	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
834	Recent advances in respiratory immunization: A focus on COVID-19 vaccines. <i>Journal of Controlled Release</i> , 2023, 355, 655-674.	4.8	7
835	Investigating COVID-19 Vaccination Patterns in Europe. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2023, , 219-246.	0.3	0
836	The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection. <i>Annals of Medicine</i> , 2023, 55, 722-732.	1.5	0
837	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
838	A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 513.	2.1	5
839	Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis. <i>Journal of the Formosan Medical Association</i> , 2023, , .	0.8	0
840	Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
841	The present value of human life losses associated with COVID-19 and likely cost savings from vaccination in Kenya. <i>F1000Research</i> , 0, 12, 232.	0.8	1
842	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968.	1.7	17
843	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
844	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. <i>Npj Vaccines</i> , 2023, 8, .	2.9	13
846	<scp>Observedâ€coverâ€Expected</scp> analysis as additional method for pharmacovigilance signal detection in largeâ€scaled spontaneous adverse event reporting. <i>Pharmacoepidemiology and Drug Safety</i> , 2023, 32, 783-794.	0.9	2
847	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
848	Short-term Side Effects of COVID-19 Vaccines (Astrazeneca, Sputnik-V, and Sinopharm) in Health Care Workers: A Cross-Sectional Study in Iran. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	0
849	SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison. <i>Diagnostics</i> , 2023, 13, 1194.	1.3	2

#	ARTICLE	IF	CITATIONS
850	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
851	Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
852	Assessment and Correlation of Adverse Events Following Coronavirus Disease Vaccination with Blood Group and Dietary Style. <i>Journal of the Scientific Society</i> , 2023, 50, 61.	0.1	0
854	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6369.	1.8	4
855	Adjustment of interval between doses of COVID-19 vaccine: a concern for cancerous patients. <i>Formosan Journal of Surgery</i> , 0, Publish Ahead of Print, .	0.1	0
856	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. <i>Vaccine</i> , 2023, 41, 3003-3010.	1.7	1
857	Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	0.6	1
858	Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	2
859	An assessment of the strategy and status of COVID-19 vaccination in India. <i>Immunologic Research</i> , 2023, 71, 565-577.	1.3	3
860	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12
861	The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
862	Immune interference in effectiveness of influenza and COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
863	Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand. <i>Vaccine: X</i> , 2023, 14, 100305.	0.9	1
864	Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. <i>Nature Communications</i> , 2023, 14, .	5.8	7
865	Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections. <i>IScience</i> , 2023, 26, 106716.	1.9	1
903	Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes. <i>Endocrine</i> , 2023, 82, 15-27.	1.1	2
904	Immunity and Vaccination Certificates in the Covid-19 Crisis. , 2023, , 137-147.		0
910	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0

#	ARTICLE	IF	CITATIONS
911	Vaccine Immunology. , 2023, , 17-36.e7.		0
929	India's COVID-19 Vaccination Drive: Its Relevance in Managing the Pandemic. India Studies in Business and Economics, 2023, , 199-223.	0.2	0
930	Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis. European Journal of Pediatrics, 0, , .	1.3	0